The article discusses individualized therapy for HER2-positive early-stage breast cancer. It highlights the successes of targeted therapies such as trastuzumab and pertuzumab, which form the basis of treatment in the early stages. These drugs have significantly improved the prognosis, which was previously unfavorable. HER2-positive breast cancer accounts for 15–20% of all breast cancers[1]. Studies such as APHINITY and KATHERINE confirm the optimal combinations and length of therapy[1]. The article points to the need to adapt treatment according to the molecular characteristics of the tumor. Published in the New England Journal of Medicine on February 26, 2026[1].